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Abstract
Purpose—To develop an imaging tool that enables the detection of malignant tissue with 
enhanced specificity using the exquisite spatial resolution of MRI.
Methods—Two mammalian gene expression vectors were created for the expression of the 
lysine-rich protein (LRP) under the control of the cytomegalovirus (CMV) promoter and the 
progression elevated gene-3 promoter (PEG-3 promoter) for constitutive and tumor-specific 
expression of LRP, respectively. Using those vectors, stable cell lines of rat 9L glioma, 
9LCMV-LRP and 9LPEG-LRP, were established and tested for CEST contrast in vitro and in vivo.
Results—9LPEG-LRP cells showed increased CEST contrast compared with 9L cells in vitro. 
Both 9LCMV-LRP and 9LPEG-LRP cells were capable of generating tumors in the brains of mice, 
with a similar growth rate to tumors derived from wild-type 9L cells. An increase in CEST 
contrast was clearly visible in tumors derived from both 9LCMV-LRP and 9LPEG-LRP cells at 3.4 
ppm.
*Correspondence to: Martin G. Pomper, M.D., Ph.D., Johns Hopkins Medical School, 1550 Orleans Street, 492 CRB II, Baltimore, 
MD 21287-0014. mpomper@jhmi.edu. 
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Conclusion—The PEG-3 promoter:LRP system can be used as a cancer-specific, molecular-
genetic imaging reporter system in vivo. Because of the ubiquity of MR imaging in clinical 
practice, sensors of this class can be used to translate molecular-genetic imaging rapidly.
Keywords
molecular imaging; chemical exchange saturation transfer; PEG-3 promoter; glioma; magnetic 
resonance imaging
INTRODUCTION
Molecular-genetic MRI uses reporter-imaging probe pairs that can generate MR contrast (1). 
The goal of molecular-genetic MRI is to leverage the superior three-dimensional spatial 
resolution of MRI to develop reporter-based, targeted MRI systems. Many reporters have 
been identified as candidate MR contrast-generating genes. Those include: the β-
galactosidase-Gd3+-containing galactopyranosyl ring reporter-probe pair for T1 contrast (2); 
the tyrosinase-paramagnetic iron pair for T2 contrast (3); the transferrin receptor-
monocrystalline iron oxide nanocompound pair for T2 contrast (4); the ferritin and 
endogenous iron pair for T2 contrast (5,6); the Mag A-iron pair for T2 contrast (7); and, the 
secreted alkaline phosphatase (SEAP)-phospho-rylated metalloporphyrin pair for T1 contrast 
(8). We have developed an artificial gene, the lysine-rich protein (LRP), as a reporter for 
chemical exchange saturation transfer (CEST) MRI (9). The LRP provides a high density of 
amide protons, which enables detection by MRI without requiring administration of a 
cognate probe. LRP-expressing tumors in the mouse brain have been imaged by CEST MRI 
(9).
For imaging reporter genes to be applied in a target-specific manner, they should either be 
delivered exclusively to their targets or expressed specifically within the target cells. The 
latter can be accomplished by using a target-selective promoter to drive the expression of a 
reporter following systemic delivery of a reporter plasmid. Many promoters of genes with 
elevated expression in human cancers have been examined as potential cancer-specific 
promoters, but most are active only in cancers of certain tissues of origin (10,11). The 
optimal promoters for cancer-specific, molecular-genetic imaging would be active in a 
variety of human cancers, while remaining minimally active or silent in normal tissues. We 
have identified a minimal promoter from a rodent gene, the progression elevated gene-3 
(PEG-3 promoter), through subtraction hybridization while searching for genes involved in 
malignant transformation and tumor progression (12). We found that the PEG-3 promoter 
behaves as a cancer-specific promoter as it is active in a variety of human cancers, including 
brain, prostate, breast, pancreatic, and skin cancers, with minimal activity in normal 
counterpart tissues (13–16). Tumor specificity of the PEG-3 promoter has been attributed to 
binding sites of two transcription factors, AP-1 and PEA-3 (or E1AF, the human homolog), 
which are reported to be overexpressed in human cancer cells (13). Systemic delivery of the 
PEG-3 promoter-reporter plasmid followed by imaging with bioluminescence or single 
photon emission computed tomography (SPECT) enabled detection of micrometastases in 
experimental models of human breast cancer and melanoma (17). However, 
bioluminescence imaging cannot extend beyond preclinical models and SPECT is fraught 
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with relatively low spatial resolution. Accordingly we turned to MRI with the PEG-3 
promoter to drive production of LRP in a cancer-specific manner with the high spatial 
resolution of this modality.
The LRP is based on CEST, a relatively new MR contrast mechanism (18–20). CEST allows 
detection of bioorganic molecules, such as proteins (21,22), polysaccharides (23,24), 
metabolites (25–27), enzyme substrates (28–31) as well as injectable compounds (32) due to 
the exchange of MR-saturable, labile protons in these molecules with those of water. Here, 
we present a molecular-genetic imaging approach to detect tumor-specific gene expression 
in an animal model of glioma by using the MR reporter gene LRP and CEST MRI. The LRP 
was expressed under control of the tumor-specific PEG-3 promoter in rat 9L glioma cells 
(9LPEG-LRP). 9LPEG-LRP cells transplanted to a mouse brain showed higher CEST contrast 
compared with that from similarly transplanted wild-type cells. Our results demonstrate the 
feasibility of using a CEST-based reporter gene under a tumor-specific promoter for 
detection of tumors in vivo with MRI.
METHODS
In Vitro Assessment of PEG-Promoter Activity
The dual-luciferase assay was carried out to measure promoter activities in rat 9L glioma 
cells. 9L cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum and 1× 
penicillin and streptomycin in a humidified incubator (37°C, 5% CO2). 9L cells were seeded 
in 24-well plates (1 × 105 cells per well). Forty-eight hours later, cells were transiently 
transfected with the following combination of plasmids using jetPRIME® according to the 
manufacturer's instructions (Polyplus-Transfection Inc., Illkirch, France); (i) pPEG-Luc (17) 
+ pGL4.74 (Promega, Madison, WI), (ii) pCMV-Tri (17) + pGL4.74, and (iii) pGL3-basic 
(Promega, Madison WI) + pGL4.74 with a 10:1 ratio for each preparation. pPEG-Luc 
possess PEG-3 promoter driven firefly luciferase (fLuc), pCMV-Tri has CMV promoter 
driven fLuc, and pGL3-basic plasmid has no promoter, serving as a promoterless control. 
pGL4.74 plasmid expresses Renilla luciferase (rLuc) to normalized the transfection 
efficiency. At 48 h post-transfection, fLuc activity was measured using the Dual-
Luciferase® Reporter Assay System (Promega). The fLuc activity was normalized to rLuc 
activity and total protein amount measured by the Coomasie® protein assay reagent kit 
(Pierce Biotechnology, Rockford, IL).
Cloning of the Expression Constructs
The pMONO-neo-mcs vector was purchased from InvivoGen (San Diego, CA) and the 
ferritin heavy chain core promoter was replaced with the PEG-3 promoter to create pPEG-
neo-mcs. Lysine-rich protein (LRP), which consists of four repeats of 
‘MGKKKKKKKKKKKKKKKKKKKKKKKKGS’ and a V5 tag, was amplified by 
polymerase chain reaction (PCR) using pLRP101 (9) as a template and inserted into pPEG-
neo-msc and pCEP4 (Life Technologies, Carlsbad, CA) to create pPEG-LRP and pCMV-
LRP, respectively. The sequence of the vector was confirmed (MacrogenUSA, Rockville, 
MD). Primers used for PCR were as follows: PEG-3 Promoter for pPEG-neo-msc (Forward: 
CAGAACTAGTAGAAAGAGAAAGAGAATGGGAC; Reverse: AAC 
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AGGATCCGTCCGGTTCGGTTTGC CAAAAGCG), LRP for pPEG-LRP (Forward: 
CTAAATCG ATCCATCATTTGTACAAAAAAGCAGGCTCCG; Reverse: 
AGCACCTAGGTTACTAACCGGTACGCGTAGAATCGAG), LRP for pCMV-LRP 
(Forward: CAGTAAGCTTCCATCAT TTGTACAAAAAAGCAGGCTCCG; Reverse: 
CACAATCTC GAGTTAC TAACCGGTACGCGTAGAATCGAG).
Establishing a Stable Cell Line Expressing pPEG-LRP and pCMV-LRP
9L cells were transfected separately with pPEG-LRP and pCMV-LRP using Lipofectamine 
2000 (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. 
9LPEG-LRP and 9LCMV-LRP were selected by maintaining cells after the transfection in 
growth medium containing 1 mg/mL of G-418 (Life Technologies, Carlsbad, CA) and 100 
μg/mL of Hygromycin B (Corning Cell-gro, Manassas, VA), respectively.
In Vitro CEST MRI
In vitro CEST MRI experiments were performed as previously described (33,34) with the 
following modifications. In brief, 1 × 107 cells were placed in a 5 mm NMR tube (three 
tubes from three separate preparations, for each cell type, 9L or 9LPEG-LRP) and placed 
within a vertical-bore 11.7T Bruker Avance system (Bruker Biosciences Corp., Billerica, 
MA) at 37°C. A modified RARE (repetition time/echo time [TR/TE] = 5000/20 ms, RARE 
factor = 8, 1 mm slice thickness, field of view (FOV) = 1.7 × 1.7 cm, matrix size = 128 × 64, 
resolution = 0.17 × 0.34 mm, and NA = 2) sequence, including a magnetization transfer 
(MT) module (B1 = 3.6 μT/3000 ms) was used to acquire CEST weighted images from −4.4 
ppm to +4.4 ppm (step = 0.2 ppm) around the water resonance (0 ppm). For B0 shift 
correction of each pixel in the CEST image, the absolute water resonant frequency shift was 
measured using a modified Water Saturation Shift Reference (WASSR) method (35), using 
the same parameters as in CEST imaging except TR = 1500 ms, saturation pulse of 500 ms, 
B1 = 0.5 μT and a sweep range from −1 ppm to 1 ppm (step = 0.1 ppm).
Animal Model
NOD/SCID/IL2rγnull (NSG) mice were purchased from the Animal Resource Core of the 
Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins. Mice were anaesthetized 
by inhaling 1.5% isoflurane/oxygen gas. Small holes were made on the skull at 2 mm lateral 
to the bregma. 2 × 105 cells in 2 μL of media were directly injected into the striatum 3 mm 
deep from the skull using a 24 gauge Hamilton syringe over 5 min. Animal experiments 
were performed in accordance with protocols approved by Johns Hopkins Animal Care and 
Use Committee (ACUC).
In Vivo CEST MRI
Mice with bilateral tumors within striatum (9L and 9LPEG-LRP, n = 8) and (9L and 
9LCMV-LRP, n = 1) were used. Data were acquired using a horizontal-bore 11.7 Tesla (T) 
MRI scanner (Bruker Biospec) equipped with a circular polarized MRI transceiver coil (ID 
= 23 mm). Seven days after cell transplantation, mice were anesthetized with 1.5% 
isoflurane and CEST data were obtained as previously described (33,36), and with the 
following parameters: A single 1 mm slice with FOV of 1.6 × 1.6 cm2 and a 96 × 48 matrix 
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were used, resulting in an in-plane resolution of 0.167 × 0.333 mm. CEST-weighted images 
were acquired with a modified RARE pulse sequence (TR/TE = 6000/35 ms), using a 3.6 
μT/3000 ms saturation pulse from −4.2 to +4.2 ppm (0.2 ppm steps) around the water 
resonance, which was assigned to be at 0 ppm (total experimental time of 41 min). Pixel-
based B0 correction was used as described before (35) using the same parameters as above 
except for TR = 1500 ms, B1/tsat = 0.5 μT/500 ms, with a sweep range from −1 to +1 ppm 
(0.1 ppm steps). Mean CEST spectra (Z-spectra) were plotted from a region of interest 
(ROI) for each tumor and normal brain tissue, after B0 correction.
CEST Data Processing
Data processing was performed using custom-written scripts in Matlab as described earlier 
(33). Mean Z-spectra were used from a ROI for each sample, after B0 correction for each 
voxel. MTRasym = 100 × (S-Δω – SΔω)/S0 was computed at different offsets, Δω. To remove 
magnetization transfer effects, ΔMTRasym was defined as [MTRasym (tumor)] – [MTRasym 
(normal brain tissue)], as previously described (37).
Statistical Analyses
Because a series of frequencies was applied to the same sample in the in vitro CEST MRI, 
the generalized estimating equation (GEE) approach (38) was used to take into account the 
correlations across the frequencies when we compared the CEST contrast in 9L and 
9LPEG-LRP cells, and P values of the score test were reported. The GEE method was also 
applied to the comparisons in the in vivo CEST MRI study to account for the correlations 
arising from the fact that paired data of 9L and 9LPEG-LRP cells were collected from the 
same mouse and each was measured with a series of frequencies. All the tests were two-
sided. The analysis was performed using software SAS (version 9.4, Cary, NC)
RESULTS
We first examined whether the PEG-3 promoter was active in the 9L cell line. After 
transient transfection of 9L cells with pGL3-basic (no promoter control), pPEG-Luc (17), 
and pCMV-Tri (17), we measured fLuc activity driven by each promoter. The PEG-3 
promoter showed activity comparable to one third of that of the CMV promoter in 9L cells 
(Fig. 1).
To develop cell lines that stably express LRP, we created two mammalian expression 
vectors for constitutive (pCMV-LRP) and tumor-specific (pPEG-LRP) gene expression. The 
pCMV-LRP construct was equipped with the CMV promoter and the hygromycin B 
resistance gene. The pPEG-LRP construct was equipped with the tumor-specific PEG-3 
promoter and the neomycin resistance gene. To enhance the relatively weak activity of the 
PEG-3 promoter compared with the CMV promoter (Fig. 1), an SV40 enhancer and an 
SV40 polyadenylation site were inserted upstream and downstream of the PEG-3 
promoter:LRP construct, respectively. After transfecting rat 9L glioma cells with those 
vectors, we selected cells expressing LRP by maintaining them in media containing 
hygromycin B and G418 and used surviving cells (9LCMV-LRP and 9LPEG-LRP) for further 
study. We performed in vitro CEST MRI to test whether the LRP expressing cells generated 
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CEST contrast. 9LPEG-LRP cells showed increased CEST contrast compared with 9L cells at 
3.3–3.9 ppm, the frequency at which the original LRP generated contrast (9) (Fig. 2).
We then developed murine glioma models to test LRP in vivo. 9L, 9LCMV-LRP, and 
9LPEG-LRP cells were capable of forming tumors in the brains of immunocompromised NSG 
mice, as shown by T2-weighed MRI (Figs. 3a,c). An increase in CEST contrast was visible 
in tumors derived from both 9LCMV-LRP and 9LPEG-LRP cells compared with wild-type 9L 
tumors, as shown in Figs. 3b,d. We imaged a total of eight mice harboring 9L (left) and 
9LPEG-LRP (right) in the brain. The average CEST contrast, i.e., ΔMTRasym value, was 
significantly higher (P < 0.01; n = 8) for tumors derived from cells expressing LRP than 
from the wild-type 9L tumors at 3.4 ppm (Figs. 3e,f). These results demonstrate that a CEST 
reporter gene can be expressed in vivo in a tumor-specific manner and can be used as a 
tumor-specific biomarker for MR applications.
DISCUSSION
In this preclinical study, we present proof-of-principle for cancer-specific CEST MRI using 
reporter-based, molecular-genetic imaging. Many reporter genes that produce MR contrast 
for imaging have been identified and have shown promising characteristics for MR-based 
molecular-genetic imaging (10,39,40). To apply those reporters to the clinic, they should be 
selectively expressed in target cells, namely, cancer. Targeted delivery and selective 
transfection of reporter plasmid is a challenging task, especially for small or micrometastatic 
lesions. Using a target-specific promoter to control the expression of a reporter at the target 
is an alternative approach, which we have chosen. The optimal promoter for cancer-specific 
imaging would be robustly active in a wide variety of human cancers, while remaining 
inactive or minimally active in normal tissue. We leveraged the well-studied, cancer-specific 
PEG-3 promoter to drive the expression of the synthetic CEST probe, LRP. We have shown 
that the PEG-3 promoter is active in all human cancer types tested and is minimally active in 
the corresponding normal tissues (8,9,12). Because the PEG-3 promoter originated from a 
rodent genome, and humans do not have the orthologous gene, there is very little possibility 
of unwanted chromosomal insertion through homologous recombination. In addition, the 
relatively small size of the PEG-3 promoter (465 base pairs) will be an advantage for 
designing smaller imaging vectors for improved transfection efficiency (41).
The LRP does not require additional administration of the probe because the amide protons 
from the lysine residue are the source of CEST contrast. PEG-3 promoter-driven LRP 
expression with the SV40 enhancer in animal models of glioma was sufficient to generate 
detectable CEST contrast.
We designed the pPEG-LRP vector to be suitable for systemic delivery and clinical 
translation. The vector has the clinically compatible kanamycin resistance marker for the 
production of the plasmid (42). Additionally, the pPEG-LRP has a small size of 3575 base 
pairs, which can enable enhanced transfection efficiency (41). The present study 
demonstrated limited CEST contrast from LRP, potentially due to weak promoter activity of 
tumor-specific PEG-3 promoter. Further modifications of the small pPEG-LRP plasmid to 
augment the expression of LRP would enhance the sensitivity of detection. For example, a 
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two-step transcriptional amplification system can be introduced to increase the number of 
LRP molecules expressed (11,43). Adding scaffold/matrix attachment regions (S/MARs) to 
the plasmid will enable prolonged maintenance of the plasmid, resulting in accumulation of 
LRP within the transfected cancer cells. Also, using longer LRP would enhance CEST 
contrast. Indeed, CEST imaging using traditional pulse sequences, as in this study, is limited 
by low sensitivity, manifested by only a few percent change in contrast, especially for 
biological samples. This is also true for the LRP. As shown above, only a small yet 
significant (P < 0.01) change was observed. In a similar case, where LRP was used to 
monitor Oncolytic Virotherapy (44), a significant change was detected; however, it was on 
the same order of magnitude as described here. Nevertheless, CEST is an evolving field of 
MRI and new techniques that can improve the sensitivity are constantly under development, 
including methods for isolating the CEST signal from rapidly exchanging protons such as 
through length and offset varied saturation (LOVRS) (45), frequency-labeled exchange 
(FLEX) (46) as well as through separation of the contrast from endogenous contrast from 
proteins or magnetization transfer contrasts (47).
The PEG-3 promoter:LRP system enabled cancer-specific imaging using CEST MR in vivo 
in the rat 9L glioma model. Efforts to extend those findings to experimental models of 
human cancer in the periphery, with a focus on systemic delivery of the plasmid to detect 
metastatic disease, are under way.
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FIG. 1. 
a–e: Schematic diagram of the plasmids used. Promoter-less pGL3-basic (a), pPEG-fLuc 
(b), pCMV-Tri (showing only the fLuc expression cassette) (c), pCMV-LRP (d), and pPEG-
LRP (e). f: PEG-3 promoter is active in the rat 9L glioma cell line. Relative activities of 
PEG-3 promoter and CMV promoter in 9L cells were measured by the dual luciferase assay 
after transient transfection. Firefly luciferase activity was normalized to that of renilla 
luciferase and to total protein. Error bars represent standard deviation, n = 3. fLuc: firefly 
luciferase, V5: V5 tag.
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FIG. 2. 
9L cells overexpressing LRP generate CEST contrast in vitro. Rat 9L glioma cells stably 
expressing PEG-prom-driven LRP were generated to provide 9LPEG-LRP. a: In vitro CEST 
contrast in 9L vs. 9LPEG-LRP cells. b: The generalized estimating equation (GEE) approach 
demonstrated a difference in CEST contrast between wild-type and gene-tagged cells at 3.7 
ppm, n = 3.
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FIG. 3. 
PEG-3 promoter:LRP exhibited CEST contrast in a murine model of rat 9L glioma. 
Representative T2-weighted (a,c) and CEST images superimposed on T2-weighted images 
(b,d). The left hemisphere harbors the gene-tagged 9L tumor, namely, CMV-LRP in (a) and 
(b) and PEG-LRP in (c) and (d), while the right hemisphere has a tumor derived from 
implantation of wild-type 9L cells. Note that PEG-LRP enables CEST imaging due to the 
activation of PEG-3 promoter by transcription factors present in the 9L tumor cells. 
Temporal changes in the ΔMTRasym values of each tumor type (e). The generalized 
estimating equation (GEE) approach demonstrated difference in CEST contrast at 3.4 ppm 
between tumors derived from wild-type (9L) and gene-tagged (9LPEG-LRP) cells (f). The 
scale in (b and d) is of MTRasym and in (e) the scale is of ΔMTRasym. Mean ± standard 
deviation; n = 8.
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